Eko Health Appoints Justin Spencer as Chief Financial Officer. by Healthcare Executive Hires 01/09/2025 Leave a Comment. Justin Spencer, Chief Financial Officer at Eko HealthWhat You Should Know: – Eko Health, a pioneer in AI-powered heart and lung disease detection, announced today the appointment of Justin Spencer as Chief Financial Officer (CFO). – Spencer brings a wealth of experience in scaling technology companies and driving financial success, making him a valuable addition to Eko’s executive leadership team.Spencer Bio/BackgroundSpencer’s impressive track record includes serving as CFO at Vocera Communications, Symmetricom, and Covad Communications. At Vocera, he played a key role in driving growth and operational scale, which ultimately led to a $3 billion acquisition by Stryker. Spencer has held positions in corporate strategy, development, and product management, providing him with a broad operational and strategic perspective that complements his financial expertise. He also served on the Board of Directors of iPass Inc., including as Audit Committee Chair, until the company’s sale in 2019

SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, to pilot DIGITIVA™, a non-invasive digital health solution for the management of heart failure patients. In the next few weeks, eligible patients receiving care with DOHC will begin using DIGITIVA as a new method for managing their heart health while working in partnership with their healthcare team

What You Should Know:– Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, today announced the issuance of a Category III Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for its SENSORA™ platform.-The newly issued Category III CPT code will be effective on July 1, 2025, and is the first step to coverage and reimbursement for SENSORA™, bringing advanced heart disease detection to clinicians across the U.S.Eko Health: Advancing Early Cardiac Disease Detection with AI-Powered SolutionsEko Health is a leading digital health company revolutionizing the detection and monitoring of heart and lung diseases through its portfolio of digital stethoscopes, patient and provider software, and AI-driven analytics. The company’s FDA-cleared platform, used by over 500,000 healthcare professionals worldwide, enables earlier and more accurate detection, confident diagnosis, effective treatment management, and ultimately better patient care.SENSORA: AI-Enhanced Early Disease DetectionSENSORA™ is an advanced platform that empowers clinicians to detect heart disease earlier, featuring FDA-cleared AI algorithms capable of identifying signs of structural heart murmurs, low ejection fraction (Low EF), and arrhythmias such as AFib in front-line care settings. Key features include:– Seamless integration with the Eko CORE 500™ digital stethoscope, which incorporates advanced ECG technology familiar to every provider.– The ability to detect cardiac conditions that are often missed by standard care, supporting early intervention and proactive management.The Critical Role of Early Detection in Heart Disease ManagementHeart disease remains the leading cause of death in the United States, responsible for approximately 1 in 5 deaths according to the CDC. Early detection is vital for improving patient outcomes. By equipping primary care providers with the tools to identify cardiac issues at an early stage, SENSORA™ enhances proactive care, reducing the burden of managing advanced heart disease.Clinical Validation and ImpactEko’s AI algorithms have been validated in both clinical and real-world studies:– A clinical trial published in Circulation demonstrated that Eko’s AI for structural heart murmur detection doubled the sensitivity for identifying structural heart disease when compared to traditional analog stethoscopes.– In a study published in Lancet Digital Health, involving over 1,000 patients, Eko’s low ejection fraction AI accurately detected reduced ejection fraction in primary care settings, leading to its deployment in over 100 clinics in the UK by the NHS and Imperial College London.Expanding Role in Cardiac CareSENSORA’s growing significance is further demonstrated by its receipt of the Category III CPT code, which supports its expanding use across various clinical environments. This designation reflects Eko’s dedication to equipping primary care clinicians with AI tools that elevate patient care standards and bridge the gap in preventive care.“The AMA’s creation of Category III CPT code for Eko’s AI disease detection algorithms is a major step in increasing access to early heart disease detection,” said Connor Landgraf, CEO of Eko Health